Alana McNulty
Directeur/Bestuurslid bij JANUX THERAPEUTICS, INC.
Vermogen: - $ op 30-04-2024
Profiel
Alana B.
McNulty is an Independent Director at Janux Therapeutics, Inc. and Chief Business Officer at eFFECTOR Therapeutics Operations, Inc. She previously served as an Independent Director at NKGen Biotech, Inc. and General Manager & Head-Corporate Development at Advanced Tissue Sciences, Inc. Alana also held positions at The Bear Stearns Cos., Inc., Elitra Pharmaceuticals, Inc., BrainCells, Inc., Lumena Pharmaceuticals, Inc., and Excaliard Pharmaceuticals, Inc. She has a background in finance and business development.
Alana completed her undergraduate studies at the University of California, Santa Barbara and holds an MBA from UCLA Anderson School of Management.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
JANUX THERAPEUTICS, INC.
-.--% | 14-06-2023 | 0 ( -.--% ) | - $ | 30-04-2024 |
Actieve functies van Alana McNulty
Bedrijven | Functie | Begin |
---|---|---|
JANUX THERAPEUTICS, INC. | Directeur/Bestuurslid | 07-09-2021 |
eFFECTOR Therapeutics Operations, Inc.
eFFECTOR Therapeutics Operations, Inc. Miscellaneous Commercial ServicesCommercial Services eFFECTOR Therapeutics Operations, Inc. discovers and develops translation regulators. It offers small molecule therapeutics that control gene expression for the treatment of cancer and other serious diseases. Its pipeline of translation regulators includes eFT508, eIF4E, and eIF4A. The company was founded by James R. Appleman, Kevin L. Eastwood, Siegfried Reich, Davide Ruggero, Kevan Shokat, and Stephen T. Worland in 2012 and is headquartered in San Diego, CA. | Corporate Officer/Principal | 07-01-2021 |
Eerdere bekende functies van Alana McNulty
Bedrijven | Functie | Einde |
---|---|---|
EFFECTOR THERAPEUTICS, INC. | Financieel Directeur/CFO | 01-12-2020 |
Lumena Pharmaceuticals, Inc.
Lumena Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lumena Pharmaceuticals, Inc. developed oral therapeutics for rare liver diseases. The firm was engaged in the development and commercialization of novel products for rare cholestatic liver diseases and serious metabolic disorders, such as nonalcoholic steatohepatitis. The company was founded by Bronislava Gedulin and Michael G. Grey in January 2011 and was headquartered in San Diego, CA. | Financieel Directeur/CFO | 01-11-2014 |
Excaliard Pharmaceuticals, Inc.
Excaliard Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Excaliard Pharmaceuticals, Inc. manufactures, develops therapeutics for the treatment of scarring and fibrotic disorders. The company was founded by John Gordon Foulkes and Nicholas M. Dean in 2006 and is headquartered in New York, NY. | Financieel Directeur/CFO | 01-11-2011 |
BrainCells, Inc.
BrainCells, Inc. Pharmaceuticals: MajorHealth Technology BrainCells Inc. discovers and develops drugs. The company was founded by Fred H. Gage and Harry F. Hixson, Jr. in 2003 and is headquartered in San Diego, CA. | Financieel Directeur/CFO | 01-01-2011 |
Opleiding van Alana McNulty
University of California, Santa Barbara | Undergraduate Degree |
UCLA Anderson School of Management | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
JANUX THERAPEUTICS, INC. | Health Technology |
EFFECTOR THERAPEUTICS, INC. | Health Technology |
Bedrijven in privébezit | 7 |
---|---|
Advanced Tissue Sciences, Inc. | Commercial Services |
The Bear Stearns Cos., Inc.
The Bear Stearns Cos., Inc. Investment Banks/BrokersFinance Bear Stearns Cos., Inc. provides investment banking, securities trading and brokerage services. Their clients include corporations, institutions, governments and individuals. They are engaged in segments that encompass capital markets, wealth management and global clearing services. The company was founded in 1923 and is headquartered in New York, NY. | Finance |
Elitra Pharmaceuticals, Inc.
Elitra Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Elitra Pharmaceuticals, Inc. used to develop pharmaceutical products. The company employed proprietary methods for gene analysis and anti-microbial drug discovery. It used to develop technology to miniaturize anti-microbial drug screens. It was also engaged in the identification, development and commercialization of novel antimicrobial compounds that target essential gene products of pathogenic organisms. The company was founded in 1997 and was headquartered in San Diego, CA | Health Technology |
BrainCells, Inc.
BrainCells, Inc. Pharmaceuticals: MajorHealth Technology BrainCells Inc. discovers and develops drugs. The company was founded by Fred H. Gage and Harry F. Hixson, Jr. in 2003 and is headquartered in San Diego, CA. | Health Technology |
Lumena Pharmaceuticals, Inc.
Lumena Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lumena Pharmaceuticals, Inc. developed oral therapeutics for rare liver diseases. The firm was engaged in the development and commercialization of novel products for rare cholestatic liver diseases and serious metabolic disorders, such as nonalcoholic steatohepatitis. The company was founded by Bronislava Gedulin and Michael G. Grey in January 2011 and was headquartered in San Diego, CA. | Health Technology |
Excaliard Pharmaceuticals, Inc.
Excaliard Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Excaliard Pharmaceuticals, Inc. manufactures, develops therapeutics for the treatment of scarring and fibrotic disorders. The company was founded by John Gordon Foulkes and Nicholas M. Dean in 2006 and is headquartered in New York, NY. | Health Technology |
eFFECTOR Therapeutics Operations, Inc.
eFFECTOR Therapeutics Operations, Inc. Miscellaneous Commercial ServicesCommercial Services eFFECTOR Therapeutics Operations, Inc. discovers and develops translation regulators. It offers small molecule therapeutics that control gene expression for the treatment of cancer and other serious diseases. Its pipeline of translation regulators includes eFT508, eIF4E, and eIF4A. The company was founded by James R. Appleman, Kevin L. Eastwood, Siegfried Reich, Davide Ruggero, Kevan Shokat, and Stephen T. Worland in 2012 and is headquartered in San Diego, CA. | Commercial Services |